Press release: Uppsala, February 26, 2021. Senzime AB’s (publ) Year-End Report for 2020 is now available on the company’s website www.senzime.com.
- Breakthrough orders in the US, UK, France and Germany
- Out-licensing of OnZurf® Probe in a deal worth more than SEK 100 million
- Strengthened balance sheet through new share issues of SEK 170 million
Financial information for the fourth quarter 2020
- Net sales amounts to KSEK 3,494 (2,688)
- Income after financial items amounts to KSEK -15,570 (-9,616)
- Earnings per share amounts to SEK -0.26 (-0.18)
- Cash and cash equivalents amount to SEK 160.3 million (30,9) on December 31.
Financial information for January-December 2020
- Net sales amounts to KSEK 9,337 (6,711)
- Income after financial items amounts to KSEK -48,991 (-34,266)
- Earnings per share amounts to SEK -0.84 (-0.65)
“Our vision is a world where patients wake up safely after surgery. For this purpose, we have developed a medical device – TetraGraph® – with associated disposable sensors – TetraSens®. TetraGraph® is a unique digital system that measures the presence and depth of neuromuscular block during anesthesia so that the doctor can determine the correct dosage of medication and assess when the patient is ready to breathe on their own without risk of complications. The potential global market for TetraGraph® is estimated at 166,000 operating rooms, which carry out 79 million operations annually.
Senzime is in a strong growth and expansion phase with its own sales force in both the US and Germany, while we have licensees and distributors in strategic focus markets in Europe, South Korea and Japan. A listing on Nasdaq Stockholm’s main list is seen as a logical next step in the company’s development and it is with pleasure that we have recently communicated that this is underway”, says Pia Renaudin, CEO of Senzime.
Uppsala, February 2021
Pia Renaudin, CEO
For further information, please contact:
Pia Renaudin, CEO of Senzime AB
Phone: +46 70-813 34 17, e-post: firstname.lastname@example.org
Erik Bergman, CFO
Phone: +46 73-58 81 59, e-mail: email@example.com
TO THE EDITORS
Senzime develops and markets systems, driven by unique algorithms and sensors, to follow patients ' nervous systems and electrical impulses – before, during and after surgery. The company's solution is called TetraGraph, a medical technology system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow health care guidelines and drug recommendations, TetraGraph contributes to shorter hospitalizations and lower health care costs – in a world where everyone wakes up safely after surgery. The vision is a world without narcotics-related complications. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, firstname.lastname@example.org, is Certified Adviser for Senzime. www.senzime.com
This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on February 26, 2021, 08:45.
PM Senzime Year-End Summary 2020